{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Merck & Company Inc", "name": "organizations", "rank": "11", "is_major": "N"}, {"value": "Skin Cancer", "name": "subject", "rank": "12", "is_major": "N"}, {"value": "Lung Cancer", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "New England Journal of Medicine", "name": "organizations", "rank": "3", "is_major": "Y"}, {"value": "Tumors", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Immune System", "name": "subject", "rank": "5", "is_major": "N"}, {"value": "Research", "name": "subject", "rank": "6", "is_major": "N"}, {"value": "Colon and Colorectal Cancer", "name": "subject", "rank": "7", "is_major": "N"}, {"value": "Prostate Cancer", "name": "subject", "rank": "8", "is_major": "N"}, {"value": "American Society of Clinical Oncology", "name": "organizations", "rank": "9", "is_major": "N"}, {"value": "Bristol Myers Squibb Company", "name": "organizations", "rank": "10", "is_major": "N"}], "web_url": "http://www.nytimes.com/2015/05/30/business/new-class-of-drugs-shows-more-promise-in-treating-cancer.html", "document_type": "article", "byline": {"person": [{"lastname": "POLLACK", "firstname": "Andrew", "role": "reported", "organization": "", "rank": 1}], "original": "By ANDREW POLLACK"}, "type_of_material": "News", "multimedia": [{"url": "images/2015/05/30/business/30lung-web/30lung-web-thumbWide.jpg", "legacy": {"wide": "images/2015/05/30/business/30lung-web/30lung-web-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2015/05/30/business/30lung-web/30lung-web-articleLarge.jpg", "legacy": {"xlarge": "images/2015/05/30/business/30lung-web/30lung-web-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2015/05/30/business/30lung-web/30lung-web-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/05/30/business/30lung-web/30lung-web-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1109", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "A study sheds light on why the new medicines seem to work for some cancers and not others.", "pub_date": "2015-05-30T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "New Promise in New Class of Drugs for Cancer", "main": "New Class of Drugs Shows More Promise in Treating Cancer"}, "print_page": "3", "snippet": "A study sheds light on why the new medicines seem to work for some cancers and not others.", "_id": "5568a95538f0d87c79ae5f42", "slideshow_credits": null, "abstract": "Doctors presenting at annual meeting of American Society of Clinical Oncology report on new class of drugs that spur body's immune system to attack tumors, and can prolong lives of people with most common form of lung cancer; separate study, published in New England Journal of Medicine, finds particular genetic signature in tumor can help predict which patients could benefit from these immune-boosting drugs."}